Pharmaceuticals, Biotechnology and Life Sciences
Pacific Biosciences of California’s CEO Michael Hunkapiller, Ph.D. is retiring as Chief Executive Officer and President by the end of the year, while planning to remain on the Board of Directors.
Pacific Biosciences of California is working with commercial, academic and government research teams that are investigating SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic.
Pacific Biosciences’ Single Molecule, Real-Time Sequencing technology has been selected by the European research program SOLVE-RD to help reveal the genetic mechanisms responsible for rare genetic diseases. As part of this work, scientists will sequence more than 500 whole human genomes with the PacBio Sequel II System to pinpoint disease-causing variants.
Illumina will acquire Pacific Biosciences for $1.2 billion, it was revealed on Friday, after the agreement had been approved by the board of directors of Illumina and Pacific Biosciences.
$ILMN $PACB
Pacific Biosciences of California has patented its methods for single molecule sequencing of concatemers having complementary sense and antisense regions…
Pacific Biosciences of California said in its fourth quarter results announcement that it has had 19% of increase in product, service…